Case 75 – update 3

Bortezomib-based regimes are associated with better outcomes as it more rapidly reduces tumour load and reverses complications.

What would you combine Bortezomib with in our patient?

How would you consolidate this treatment if response achieved?

Would the cytogenetics results influence your treatment options?

Please reply with #Teamhaem so everyone can be involved!

About TeamHaem

Online education and discussion about all things haematological
This entry was posted in Myeloma/paraproteins and tagged , , . Bookmark the permalink.